Immunovant (IMVT)
Immunovant on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
18.3M
Short interest
settlement 2026-10-15
12.3
Days to cover
+2.7 days vs prior
42.2%
Short share of volume
2026-11-02
38
Fails to deliver
settlement 2026-10-07
Mon 9 Nov
Next earnings
estimated date
-$923K
Insider flow, 90 days
0 buys, 10 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in IMVT is 18,273,675 shares, up 1,019,727 shares over the last month. Over the last 48 readings it ranged from 12,260,769 shares (31 December 2024) to 21,679,283 shares (30 May 2025). At the reported average volume of 1.5M shares a day that is 12.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/imvt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 18,273,675 | +4.9% | 1,479,066 | 12.35 |
| 2026-09-30 | 17,416,613 | +0.9% | 1,805,887 | 9.64 |
| 2026-09-15 | 17,253,948 | +9.3% | 1,203,127 | 14.34 |
| 2026-08-31 | 15,784,450 | -7.0% | 1,123,305 | 14.05 |
| 2026-08-14 | 16,981,939 | +3.7% | 1,126,554 | 15.07 |
| 2026-07-31 | 16,375,679 | -7.8% | 884,266 | 18.52 |
| 2026-07-15 | 17,758,956 | -1.3% | 1,062,352 | 16.72 |
| 2026-06-30 | 17,991,218 | -7.0% | 2,085,654 | 8.63 |
| 2026-06-15 | 19,342,026 | +0.7% | 1,373,064 | 14.09 |
| 2026-05-29 | 19,208,923 | -5.7% | 3,848,981 | 4.99 |
| 2026-05-15 | 20,368,530 | +9.6% | 1,244,653 | 16.36 |
| 2026-04-30 | 18,590,270 | -4.7% | 1,772,681 | 10.49 |
| 2026-04-15 | 19,500,601 | +5.8% | 1,410,622 | 13.82 |
| 2026-03-31 | 18,430,920 | +11.3% | 1,491,046 | 12.36 |
| 2026-03-13 | 16,565,490 | -1.6% | 1,028,071 | 16.11 |
| 2026-02-27 | 16,835,365 | -0.7% | 877,005 | 19.20 |
| 2026-02-13 | 16,951,530 | +2.8% | 1,665,252 | 10.18 |
| 2026-01-30 | 16,487,739 | -2.6% | 1,256,815 | 13.12 |
| 2026-01-15 | 16,933,015 | +4.9% | 1,742,359 | 9.72 |
| 2025-12-31 | 16,135,139 | +7.8% | 1,650,816 | 9.77 |
| 2025-12-15 | 14,964,704 | -0.7% | 2,092,455 | 7.15 |
| 2025-11-28 | 15,067,824 | -8.0% | 1,178,809 | 12.78 |
| 2025-11-14 | 16,381,611 | +1.0% | 1,620,865 | 10.11 |
| 2025-10-31 | 16,214,977 | -4.7% | 2,230,403 | 7.27 |
| 2025-10-15 | 17,009,989 | +4.6% | 1,479,864 | 11.49 |
| 2025-09-30 | 16,268,540 | +0.8% | 1,849,964 | 8.79 |
| 2025-09-15 | 16,147,300 | +3.7% | 2,091,376 | 7.72 |
| 2025-08-29 | 15,570,264 | -3.1% | 1,123,865 | 13.85 |
| 2025-08-15 | 16,067,954 | -2.2% | 1,135,066 | 14.16 |
| 2025-07-31 | 16,428,594 | -20.1% | 1,378,765 | 11.92 |
| 2025-07-15 | 20,574,064 | +0.6% | 1,173,113 | 17.54 |
| 2025-06-30 | 20,443,952 | +2.6% | 1,360,508 | 15.03 |
| 2025-06-13 | 19,918,341 | -8.1% | 1,442,332 | 13.81 |
| 2025-05-30 | 21,679,283 | +1.3% | 1,135,997 | 19.08 |
| 2025-05-15 | 21,397,625 | +3.3% | 1,166,225 | 18.35 |
| 2025-04-30 | 20,710,025 | -0.6% | 1,489,137 | 13.91 |
| 2025-04-15 | 20,832,400 | +5.8% | 2,630,259 | 7.92 |
| 2025-03-31 | 19,685,000 | +24.6% | 2,625,510 | 7.50 |
| 2025-03-14 | 15,799,702 | +2.7% | 1,090,795 | 14.48 |
| 2025-02-28 | 15,390,952 | +4.1% | 990,020 | 15.55 |
| 2025-02-14 | 14,788,106 | +12.5% | 1,658,194 | 8.92 |
| 2025-01-31 | 13,149,997 | +2.5% | 1,319,745 | 9.96 |
| 2025-01-15 | 12,832,296 | +4.7% | 960,266 | 13.36 |
| 2024-12-31 | 12,260,769 | -2.9% | 1,098,414 | 11.16 |
| 2024-12-13 | 12,631,893 | -0.3% | 803,014 | 15.73 |
| 2024-11-29 | 12,665,555 | -2.7% | 933,577 | 13.57 |
| 2024-11-15 | 13,015,453 | -0.7% | 861,542 | 15.11 |
| 2024-10-31 | 13,101,374 | +1.3% | 670,378 | 19.54 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of IMVT volume is 42.2%, down 22.8 points over the last five sessions. Over the last 30 readings it ranged from 31.2% (28 October 2026) to 86.6% (21 October 2026). The latest reading is 18.0 points below the 30-session average of 60.2%, on 577K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 243K | 577K | 42.2% | 0 |
| 2026-10-30 | 187K | 303K | 61.5% | 926 |
| 2026-10-29 | 300K | 671K | 44.6% | 5,944 |
| 2026-10-28 | 166K | 532K | 31.2% | 1,855 |
| 2026-10-27 | 156K | 491K | 31.8% | 0 |
| 2026-10-26 | 287K | 441K | 65.0% | 0 |
| 2026-10-23 | 127K | 176K | 72.1% | 0 |
| 2026-10-22 | 210K | 410K | 51.1% | 0 |
| 2026-10-21 | 461K | 533K | 86.6% | 9,284 |
| 2026-10-20 | 220K | 605K | 36.4% | 182 |
| 2026-10-19 | 312K | 522K | 59.7% | 0 |
| 2026-10-16 | 262K | 400K | 65.4% | 0 |
| 2026-10-15 | 315K | 613K | 51.3% | 0 |
| 2026-10-14 | 289K | 448K | 64.4% | 52 |
| 2026-10-13 | 217K | 417K | 52.1% | 5 |
| 2026-10-12 | 434K | 972K | 44.7% | 0 |
| 2026-10-09 | 350K | 467K | 75.0% | 0 |
| 2026-10-08 | 441K | 588K | 75.1% | 0 |
| 2026-10-07 | 393K | 470K | 83.6% | 432 |
| 2026-10-06 | 402K | 577K | 69.6% | 0 |
| 2026-10-05 | 132K | 280K | 47.2% | 0 |
| 2026-10-02 | 192K | 288K | 66.6% | 1,016 |
| 2026-10-01 | 317K | 421K | 75.3% | 0 |
| 2026-09-30 | 283K | 410K | 69.0% | 4,305 |
| 2026-09-29 | 248K | 441K | 56.3% | 0 |
| 2026-09-28 | 260K | 433K | 60.2% | 232 |
| 2026-09-25 | 344K | 653K | 52.7% | 0 |
| 2026-09-24 | 454K | 609K | 74.7% | 662 |
| 2026-09-23 | 1.1M | 1.6M | 67.5% | 195 |
| 2026-09-22 | 391K | 537K | 72.9% | 4,676 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 7 October 2026, the fails-to-deliver balance in IMVT is 38 shares, down 943 shares over the last settlement date. Over the last 30 readings it ranged from 15 shares (1 July 2026) to 102,234 shares (21 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-07 | 38 | $32.11 | $1K |
| 2026-09-08 | 981 | $39.25 | $39K |
| 2026-09-04 | 7,669 | $39.12 | $300K |
| 2026-08-28 | 1,149 | $43.82 | $50K |
| 2026-08-24 | 141 | $44.37 | $6K |
| 2026-08-20 | 3,128 | $44.96 | $141K |
| 2026-08-14 | 1,012 | $41.82 | $42K |
| 2026-08-13 | 1,281 | $42.60 | $55K |
| 2026-08-05 | 1,656 | $39.36 | $65K |
| 2026-08-04 | 100 | $38.51 | $4K |
| 2026-08-03 | 502 | $38.62 | $19K |
| 2026-07-30 | 40 | $38.61 | $2K |
| 2026-07-23 | 29 | $39.05 | $1K |
| 2026-07-20 | 76 | $40.26 | $3K |
| 2026-07-14 | 145 | $38.70 | $6K |
| 2026-07-01 | 15 | $38.53 | $578 |
| 2026-06-30 | 2,329 | $38.51 | $90K |
| 2026-06-29 | 93,816 | $38.85 | $3.6M |
| 2026-06-26 | 398 | $38.24 | $15K |
| 2026-06-22 | 700 | $35.34 | $25K |
| 2026-06-18 | 42 | $34.71 | $1K |
| 2026-06-11 | 638 | $31.18 | $20K |
| 2026-05-26 | 168 | $34.15 | $6K |
| 2026-05-22 | 18 | $34.13 | $614 |
| 2026-05-21 | 102,234 | $35.56 | $3.6M |
| 2026-05-18 | 679 | $27.49 | $19K |
| 2026-05-01 | 14,027 | $27.15 | $381K |
| 2026-04-07 | 218 | $24.89 | $5K |
| 2026-04-06 | 259 | $24.50 | $6K |
| 2026-03-24 | 139 | $24.38 | $3K |
Insider trades
SEC Form 4, newest first. JSONInsiders at IMVT reported 10 open-market sells worth $923K in the last 90 days and no open-market buys. Latest filing: Girao Tiago (Chief Financial Officer) on 2026-10-28.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-28 | Girao Tiago | Chief Financial Officer | Sell | 7K | $28.50 | $188K | 234K |
| 2026-10-21 | Stout Jay S | Chief Technology Officer | Sell | 3K | $28.94 | $75K | 199K |
| 2026-10-07 | Gloria Melanie | Chief Operating Officer | Sell | 2K | $32.06 | $72K | 217K |
| 2026-10-07 | Van Tuyl Christopher | Chief Legal Officer | Sell | 1K | $32.06 | $43K | 175K |
| 2026-10-07 | Stout Jay S | Chief Technology Officer | Sell | 2K | $32.06 | $51K | 202K |
| 2026-10-07 | Stout Jay S | Chief Technology Officer | Sell | 2K | $32.06 | $71K | 203K |
| 2026-10-02 | Venker Eric | Chief Executive Officer | Sell | 4K | $34.11 | $120K | 257K |
| 2026-10-01 | Venker Eric | Chief Executive Officer | Returned to company | 86K | $33.65 | $2.9M | 261K |
| 2026-10-01 | Venker Eric | Chief Executive Officer | Exercise or conversion | 92K | $14.46 | $1.3M | 346K |
| 2026-09-23 | Van Tuyl Christopher | Chief Legal Officer | Sell | 3K | $36.36 | $103K | 177K |
| 2026-08-28 | Pande Atul | Director | Sell | 2K | $43.27 | $65K | 117K |
| 2026-08-28 | Pande Atul | Director | Exercise or conversion | 2K | $8.43 | $13K | 118K |
| 2026-08-20 | Gloria Melanie | Chief Operating Officer | Sell | 3K | $44.16 | $135K | 219K |
| 2026-07-24 | Pande Atul | Director | Sell | 2K | $39.80 | $60K | 117K |
| 2026-07-24 | Pande Atul | Director | Exercise or conversion | 2K | $8.43 | $13K | 118K |
| 2026-07-23 | Stout Jay S | Chief Technology Officer | Sell | 3K | $38.69 | $111K | 205K |
| 2026-07-23 | Girao Tiago | Chief Financial Officer | Sell | 7K | $38.69 | $263K | 241K |
| 2026-07-08 | Van Tuyl Christopher | Chief Legal Officer | Sell | 63 | $39.99 | $3K | 179K |
| 2026-07-08 | Van Tuyl Christopher | Chief Legal Officer | Sell | 1K | $39.53 | $45K | 179K |
| 2026-07-08 | Stout Jay S | Chief Technology Officer | Sell | 77 | $39.99 | $3K | 208K |
| 2026-07-08 | Stout Jay S | Chief Technology Officer | Sell | 1K | $39.53 | $55K | 208K |
| 2026-07-08 | Stout Jay S | Chief Technology Officer | Sell | 105 | $39.99 | $4K | 210K |
| 2026-07-08 | Stout Jay S | Chief Technology Officer | Sell | 2K | $39.53 | $75K | 210K |
| 2026-07-08 | Gloria Melanie | Chief Operating Officer | Sell | 106 | $39.99 | $4K | 222K |
| 2026-07-08 | Gloria Melanie | Chief Operating Officer | Sell | 2K | $39.53 | $76K | 222K |
| 2026-07-02 | Venker Eric | Chief Executive Officer | Sell | 3K | $38.48 | $119K | 254K |
| 2026-07-01 | Venker Eric | Chief Executive Officer | Returned to company | 87K | $38.14 | $3.3M | 257K |
| 2026-07-01 | Venker Eric | Chief Executive Officer | Exercise or conversion | 92K | $14.46 | $1.3M | 344K |
| 2026-06-26 | Pande Atul | Director | Sell | 2K | $38.01 | $57K | 117K |
| 2026-06-26 | Pande Atul | Director | Exercise or conversion | 2K | $8.43 | $13K | 118K |
| 2026-06-26 | Girao Tiago | Chief Financial Officer | Exercise or conversion | 10K | $15.90 | $159K | 258K |
| 2026-06-26 | Girao Tiago | Chief Financial Officer | Sell | 10K | $38.46 | $385K | 248K |
| 2026-06-26 | Van Tuyl Christopher | Chief Legal Officer | Exercise or conversion | 18K | $15.20 | $271K | 198K |
| 2026-06-26 | Van Tuyl Christopher | Chief Legal Officer | Sell | 15K | $38.19 | $572K | 183K |
| 2026-06-26 | Van Tuyl Christopher | Chief Legal Officer | Sell | 3K | $38.96 | $111K | 181K |
| 2026-06-26 | Stout Jay S | Chief Technology Officer | Sell | 33K | $38.18 | $1.3M | 218K |
| 2026-06-26 | Stout Jay S | Chief Technology Officer | Sell | 7K | $38.94 | $262K | 212K |
| 2026-06-26 | Gloria Melanie | Chief Operating Officer | Sell | 3K | $38.95 | $116K | 224K |
| 2026-06-26 | Gloria Melanie | Chief Operating Officer | Sell | 15K | $38.18 | $563K | 227K |
| 2026-06-18 | Van Tuyl Christopher | Chief Legal Officer | Sell | 3K | $35.39 | $93K | 181K |
| 2026-06-15 | Pande Atul | Director | Exercise or conversion | 2K | $8.43 | $13K | 118K |
| 2026-06-15 | Pande Atul | Director | Sell | 2K | $34.02 | $51K | 117K |
| 2026-05-28 | Fromkin Andrew J. | Director | Sell | 210K | $33.56 | $7.1M | 74K |
| 2026-05-28 | Fromkin Andrew J. | Director | Sell | 11K | $32.64 | $375K | 285K |
| 2026-05-28 | Fromkin Andrew J. | Director | Exercise or conversion | 16K | $14.70 | $239K | 296K |
| 2026-05-28 | Fromkin Andrew J. | Director | Exercise or conversion | 77K | $8.43 | $651K | 280K |
| 2026-05-28 | Fromkin Andrew J. | Director | Exercise or conversion | 71K | $7.94 | $568K | 203K |
| 2026-05-28 | Fromkin Andrew J. | Director | Exercise or conversion | 32K | $4.99 | $158K | 131K |
| 2026-05-20 | Pande Atul | Director | Sell | 6K | $32.00 | $192K | 117K |
| 2026-05-20 | Pande Atul | Director | Exercise or conversion | 6K | $8.43 | $51K | 123K |
| 2026-05-20 | Gloria Melanie | Chief Operating Officer | Sell | 2K | $32.95 | $56K | 242K |
| 2026-05-20 | Gloria Melanie | Chief Operating Officer | Sell | 1K | $32.15 | $38K | 244K |
| 2026-05-20 | Gloria Melanie | Chief Operating Officer | Sell | 249 | $30.41 | $8K | 245K |
| 2026-05-01 | Susman Robert Graham | Director | Sell | 3K | $27.17 | $68K | 36K |
| 2026-04-23 | Stout Jay S | Chief Technology Officer | Sell | 3K | $29.62 | $82K | 252K |
| 2026-04-23 | Girao Tiago | Chief Financial Officer | Sell | 26K | $29.62 | $763K | 248K |
| 2026-04-08 | Van Tuyl Christopher | Chief Legal Officer | Sell | 5K | $24.83 | $128K | 183K |
| 2026-04-08 | Stout Jay S | Chief Technology Officer | Sell | 2K | $24.83 | $38K | 254K |
| 2026-04-08 | Stout Jay S | Chief Technology Officer | Sell | 9K | $24.83 | $214K | 256K |
| 2026-04-08 | Gloria Melanie | Chief Operating Officer | Sell | 9K | $24.83 | $217K | 245K |
| 2026-04-07 | Torti Frank | Director | Grant | 174K | $0.00 | $0 | 1.0M |
| 2026-04-07 | Pande Atul | Director | Grant | 14K | $0.00 | $0 | 117K |
| 2026-04-07 | Susman Robert Graham | Director | Grant | 14K | $0.00 | $0 | 39K |
| 2026-04-07 | Stout Jay S | Chief Technology Officer | Grant | 67K | $0.00 | $0 | 265K |
| 2026-04-07 | Van Tuyl Christopher | Chief Legal Officer | Grant | 41K | $0.00 | $0 | 188K |
| 2026-04-07 | Venker Eric | Chief Executive Officer | Grant | 232K | $0.00 | $0 | 252K |
| 2026-04-07 | Hughes Douglas J. | Director | Grant | 14K | $0.00 | $0 | 135K |
| 2026-04-07 | Gloria Melanie | Chief Operating Officer | Grant | 84K | $0.00 | $0 | 254K |
| 2026-04-07 | Girao Tiago | Chief Financial Officer | Grant | 65K | $0.00 | $0 | 273K |
| 2026-04-07 | Fromkin Andrew J. | Director | Grant | 14K | $0.00 | $0 | 100K |
| 2026-04-07 | Bauer Jake | Director | Grant | 14K | $0.00 | $0 | 39K |
| 2026-04-02 | Venker Eric | Chief Executive Officer | Sell | 1K | $24.60 | $35K | 20K |
| 2026-04-02 | Venker Eric | Chief Executive Officer | Sell | 13K | $24.04 | $308K | 21K |
| 2026-04-01 | Venker Eric | Chief Executive Officer | Returned to company | 335K | $25.10 | $8.4M | 34K |
| 2026-04-01 | Venker Eric | Chief Executive Officer | Exercise or conversion | 369K | $14.46 | $5.3M | 369K |
| 2026-03-18 | Van Tuyl Christopher | Chief Legal Officer | Sell | 3K | $24.97 | $72K | 147K |
| 2026-02-25 | Gloria Melanie | Chief Operating Officer | Sell | 942 | $28.90 | $27K | 170K |
| 2026-02-25 | Gloria Melanie | Chief Operating Officer | Sell | 859 | $28.16 | $24K | 171K |
| 2026-02-25 | Gloria Melanie | Chief Operating Officer | Sell | 1K | $26.98 | $39K | 172K |
| 2026-01-21 | Stout Jay S | Chief Technology Officer | Sell | 2K | $26.03 | $51K | 198K |
| 2026-01-07 | Stout Jay S | Chief Technology Officer | Sell | 55 | $26.92 | $1K | 200K |
| 2026-01-07 | Stout Jay S | Chief Technology Officer | Sell | 1K | $26.51 | $30K | 200K |
| 2025-12-18 | Van Tuyl Christopher | Chief Legal Officer | Sell | 2K | $27.38 | $63K | 150K |
| 2025-12-18 | Van Tuyl Christopher | Chief Legal Officer | Sell | 9K | $26.78 | $228K | 152K |
| 2025-12-12 | Roivant Sciences Ltd. | Director, 10% owner | Buy | 16.7M | $21.00 | $350.0M | 113.3M |
| 2025-12-01 | Hughes Douglas J. | Director | Sell | 2K | $23.96 | $46K | 121K |
| 2025-12-01 | Hughes Douglas J. | Director | Sell | 13K | $23.14 | $303K | 123K |
| 2025-12-01 | Fromkin Andrew J. | Director | Sell | 3K | $23.95 | $69K | 86K |
| 2025-12-01 | Fromkin Andrew J. | Director | Sell | 19K | $23.14 | $448K | 89K |
| 2025-11-20 | Gloria Melanie | Chief Operating Officer | Sell | 2K | $23.97 | $57K | 174K |
| 2025-11-20 | Gloria Melanie | Chief Operating Officer | Sell | 10K | $23.54 | $241K | 176K |
| 2025-10-22 | Stout Jay S | Chief Technology Officer | Sell | 3K | $19.03 | $48K | 201K |
| 2025-10-22 | Geffner Michael | Chief Medical Officer | Sell | 3K | $19.03 | $49K | 218K |
| 2025-10-08 | Stout Jay S | Chief Technology Officer | Sell | 2K | $16.30 | $26K | 203K |
| 2025-10-08 | Geffner Michael | Chief Medical Officer | Sell | 1K | $16.30 | $21K | 221K |
| 2025-07-23 | Stout Jay S | Chief Technology Officer | Sell | 3K | $18.15 | $51K | 205K |
| 2025-07-23 | Geffner Michael | Chief Medical Officer | Sell | 2K | $18.15 | $43K | 222K |
| 2025-07-09 | Stout Jay S | Chief Technology Officer | Sell | 2K | $17.24 | $26K | 208K |
| 2025-07-09 | Geffner Michael | Chief Medical Officer | Sell | 1K | $17.24 | $20K | 224K |
| 2025-05-01 | Susman Robert Graham | Director | Grant | 25K | $0.00 | $0 | 25K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON13 Form 144 notices on file for IMVT worth $15.8M at the prices reported; 0 in the last 90 days worth $0. Latest: JAY S STOUT filed on 2026-06-26 to sell 40,000 shares ($1.5M) from 2026-06-26.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-26 | JAY S STOUTOfficer | 40K | $1.5M | 0.019% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-26 | CHRIS ADAIR VAN TUYLOfficer, Director | 18K | $683K | 0.009% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-26 | MELANIE GLORIAOfficer | 18K | $679K | 0.009% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-26 | TIAGO GIRAOOfficer | 10K | $385K | 0.005% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-15 | Atul PandeDirector | 6K | $202K | 0.003% | 2026-06-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-28 | ANDREW J FROMKINDirector | 222K | $7.4M | 0.108% | 2026-05-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-20 | Atul PandeDirector | 6K | $158K | 0.003% | 2026-05-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | ROBERT G SUSMANDirector | 3K | $68K | 0.001% | 2026-05-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-10 | MICHAEL GEFFNEROfficer | 6K | $155K | 0.003% | 2026-02-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-01 | DOUGLAS HUGHESDirector | 15K | $362K | 0.009% | 2025-12-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-01 | ANDREW J FROMKINDirector | 22K | $537K | 0.013% | 2025-12-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-26 | MICHAEL GEFFNEROfficer | 50K | $1.2M | 0.029% | 2025-11-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-25 | MICHAEL GEFFNEROfficer | 104K | $2.4M | 0.059% | 2025-11-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of IMVT in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Roivant Sciences Ltd. at 55.9% of the class (113,327,007 shares), filed 2025-12-12 for an event on 2025-12-12.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | Deep Track Capital, LPinvestment adviser, other entity | 9.3M | 4.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Deep Track Biotechnology Master Fund, Ltd.corporation | 9.3M | 4.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | David Kroinparent holding company, individual | 9.3M | 4.5% | 2026-06-30 |
| 2025-12-12 | 13D/Ano. 10 | Roivant Sciences Ltd.corporation | 113.3M | 55.9% | 2025-12-12 |
| 2025-11-05 | 13G/Ano. 3 | FMR LLCparent holding company | 14.7M | 8.4% | 2025-09-30 |
| 2025-11-05 | 13G/Ano. 3 | Abigail P. Johnsonindividual | 14.7M | 8.4% | 2025-09-30 |
13F holders
Tracked managers holding IMVT at their latest 13F. JSON6 of the 30 tracked managers held IMVT at their latest 13F, $98.7M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $47.8M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 1.2M | $47.8M | 0.02% | new |
| Renaissance Technologies | 2026-06-30 | 727K | $28.0M | 0.04% | +534K |
| Millennium Management | 2026-06-30 | 329K | $12.7M | 0.00% | new |
| Citadel Advisors | 2026-06-30 | 160K | $6.2M | 0.00% | +16K |
| Greenlight Capital (DME Capital) | 2026-06-30 | 94K | $3.6M | 0.09% | 0 |
| AQR Capital Management | 2026-06-30 | 11K | $427K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2026 it generated -$407.3M of operating cash flow.
- Cash
- $797.8M
- Equity
- $735.4M
- Total assets
- $852.5M
- Shares outstanding
- 206,552,682
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q1 FY 2027 | 2026-06-30 | n/a | -$153.2M | n/a | -0.75 |
| Q4 FY 2026derived | 2026-03-31 | n/a | -$147.9M | n/a | n/a |
| Q3 FY 2026 | 2025-12-31 | n/a | -$110.6M | n/a | -0.61 |
| Q2 FY 2026 | 2025-09-30 | n/a | -$126.5M | n/a | -0.73 |
| Q1 FY 2026 | 2025-06-30 | n/a | -$120.6M | n/a | -0.71 |
| Q4 FY 2025derived | 2025-03-31 | n/a | -$106.4M | n/a | n/a |
| Q3 FY 2025 | 2024-12-31 | n/a | -$111.1M | n/a | -0.76 |
| Q2 FY 2025 | 2024-09-30 | n/a | -$109.1M | n/a | -0.74 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2026 | 2026-03-31 | n/a | -$505.6M | -$407.3M | $8K | n/a | n/a |
| FY 2025 | 2025-03-31 | n/a | -$413.8M | -$375.9M | $759K | n/a | n/a |
| FY 2024 | 2024-03-31 | n/a | -$259.3M | -$214.2M | $360K | n/a | n/a |
| FY 2023 | 2023-03-31 | n/a | -$211.0M | -$188.2M | $197K | n/a | n/a |
| FY 2022 | 2022-03-31 | n/a | -$156.7M | -$106.1M | $254K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
Immunovant in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Immunovant (IMVT), SEC CIK 1764013, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-07.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-26.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-05-20.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-28.JSON and CSV
- Company record
- EDGAR filing index for CIK 1764013Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of IMVT is sold short?
18,273,675 shares were held short at the 2026-10-15 settlement, 12.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is IMVT's daily short volume?
On 2026-11-02, 243,402 of the 576,904 IMVT shares reported to FINRA were sold short, 42.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does IMVT have fails to deliver?
The SEC's latest file shows 38 IMVT shares failed to deliver at settlement 2026-10-07. Fails are reported per settlement date and published twice a month with a lag.
Are IMVT insiders buying or selling?
Insiders at IMVT reported 10 open-market sells worth $923K in the last 90 days and no open-market buys. Latest filing: Girao Tiago (Chief Financial Officer) on 2026-10-28.
Have IMVT insiders filed to sell?
13 Form 144 notices on file for IMVT worth $15.8M at the prices reported; 0 in the last 90 days worth $0. Latest: JAY S STOUT filed on 2026-06-26 to sell 40,000 shares ($1.5M) from 2026-06-26.
Who owns 5% or more of IMVT?
3 holders report 5% or more of IMVT in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Roivant Sciences Ltd. at 55.9% of the class (113,327,007 shares), filed 2025-12-12 for an event on 2025-12-12.
What did IMVT report last quarter?
In FY 2026 it generated -$407.3M of operating cash flow.
Which tracked 13F managers own IMVT?
6 of the 30 tracked 13F managers held IMVT shares at their latest filing, $98.7M in all. The largest: D. E. Shaw & Co. (1.2M shares, $47.8M), Renaissance Technologies (727K shares, $28.0M), Izzy Englander's Millennium Management (329K shares, $12.7M), Ken Griffin's Citadel Advisors (160K shares, $6.2M), David Einhorn's Greenlight Capital (DME Capital) (94K shares, $3.6M), Cliff Asness's AQR Capital Management (11K shares, $427K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.